Humate-P

Background

• Human Plasma-derived von Willebrand Factor
• Contains both vWF and factor VIII

Indications

• Hemophilia A (can also use factor VIII, FFP does not work well)
• Von Willebrand disease that is unresponsive to DDAVP (can also use cryoprecipitate, FFP does not work well)

Administration

• Type: blood products
• Dosage Forms:
• Routes of Administration:
• Common Trade Names:

Adult Dosing

• Von Willebrand disease
  • Major hemorrhage: loading dose 40-80 IU/kg IV
  • Minor hemorrhage: loading dose 40-50 IU/kg IV
• Hemophilia A
  • Minor hemorrhage: Loading dose 15 IU/kg IV should achieve FVIII:C plasma level ~30% of normal
  • Moderate hemorrhage: Loading dose 25 IU/kg IV should achieve FVIII:C plasma level ~50% of normal
  • Life-threatening hemorrhage: 40-50 IU/kg IV initially, followed by 2-25 IU q8-12hr to maintain FVIII:C level at 80-100% of normal

Pediatric Dosing

• Von Willebrand disease
  • Major hemorrhage: loading dose 40-80 IU/kg IV
  • Minor hemorrhage: loading dose 40-50 IU/kg IV

Special Populations

• Pregnancy Rating: C
• Lactation risk: Data limited

Renal Dosing

• Not delineated

Hepatic Dosing

• Not established

Contraindications

• Allergy to class/drug

Adverse Reactions

Serious

• Respiratory distress
• Anaphylaxis
• Thromboembolic events
• Hemolytic anemia (in massive doses)

Common

• Pain
• Pruritus
• Rash, urticaria, edema
• Fever/chills, flu-like illness, cough, pharyngitis, rhinitis
• Paresthesia
• Fatigue
• Headache
• Asthenia
• Cellulitis
• Chest pain
• Dyspepsia, nausea/vomiting
• Hepatitis

Pharmacology

• Half-life: 10-11h
• Metabolism:
• Excretion:

Mechanism of Action

• Human derived vWF

See Also

• Hemophilia
• VWD